UNIVERSAL TECHNICAL INSTITUT (UTI) Fundamental Analysis & Valuation
NYSE:UTI • US9139151040
Current stock price
37.96 USD
-1.7 (-4.29%)
At close:
37.96 USD
0 (0%)
After Hours:
This UTI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. UTI Profitability Analysis
1.1 Basic Checks
- UTI had positive earnings in the past year.
- In the past year UTI had a positive cash flow from operations.
- Each year in the past 5 years UTI has been profitable.
- UTI had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- UTI's Return On Assets of 6.44% is fine compared to the rest of the industry. UTI outperforms 73.97% of its industry peers.
- UTI has a Return On Equity of 15.98%. This is in the better half of the industry: UTI outperforms 75.34% of its industry peers.
- UTI has a better Return On Invested Capital (8.69%) than 76.71% of its industry peers.
- UTI had an Average Return On Invested Capital over the past 3 years of 7.27%. This is below the industry average of 10.75%.
- The 3 year average ROIC (7.27%) for UTI is below the current ROIC(8.69%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.44% | ||
| ROE | 15.98% | ||
| ROIC | 8.69% |
ROA(3y)4.45%
ROA(5y)3.5%
ROE(3y)11.95%
ROE(5y)9.34%
ROIC(3y)7.27%
ROIC(5y)5.89%
1.3 Margins
- With a decent Profit Margin value of 6.28%, UTI is doing good in the industry, outperforming 65.75% of the companies in the same industry.
- UTI's Profit Margin has improved in the last couple of years.
- UTI has a Operating Margin of 8.38%. This is in the better half of the industry: UTI outperforms 67.12% of its industry peers.
- UTI's Operating Margin has improved in the last couple of years.
- UTI has a Gross Margin (49.62%) which is comparable to the rest of the industry.
- UTI's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.38% | ||
| PM (TTM) | 6.28% | ||
| GM | 49.62% |
OM growth 3Y17.03%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5Y53.06%
GM growth 3Y-13.36%
GM growth 5Y-8.21%
2. UTI Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), UTI is destroying value.
- UTI has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for UTI has been increased compared to 5 years ago.
- UTI has a better debt/assets ratio than last year.
2.2 Solvency
- UTI has an Altman-Z score of 4.06. This indicates that UTI is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of UTI (4.06) is better than 79.45% of its industry peers.
- UTI has a debt to FCF ratio of 6.28. This is a slightly negative value and a sign of low solvency as UTI would need 6.28 years to pay back of all of its debts.
- UTI's Debt to FCF ratio of 6.28 is fine compared to the rest of the industry. UTI outperforms 71.23% of its industry peers.
- UTI has a Debt/Equity ratio of 0.29. This is a healthy value indicating a solid balance between debt and equity.
- UTI has a Debt to Equity ratio (0.29) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | 6.28 | ||
| Altman-Z | 4.06 |
ROIC/WACC0.99
WACC8.8%
2.3 Liquidity
- A Current Ratio of 1.14 indicates that UTI should not have too much problems paying its short term obligations.
- UTI has a Current ratio (1.14) which is comparable to the rest of the industry.
- A Quick Ratio of 1.14 indicates that UTI should not have too much problems paying its short term obligations.
- UTI's Quick ratio of 1.14 is in line compared to the rest of the industry. UTI outperforms 49.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.14 | ||
| Quick Ratio | 1.14 |
3. UTI Growth Analysis
3.1 Past
- UTI shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
- Measured over the past years, UTI shows a very strong growth in Earnings Per Share. The EPS has been growing by 65.96% on average per year.
- Looking at the last year, UTI shows a quite strong growth in Revenue. The Revenue has grown by 12.59% in the last year.
- Measured over the past years, UTI shows a very strong growth in Revenue. The Revenue has been growing by 22.67% on average per year.
EPS 1Y (TTM)0%
EPS 3Y3.11%
EPS 5Y65.96%
EPS Q2Q%-42.5%
Revenue 1Y (TTM)12.59%
Revenue growth 3Y25.89%
Revenue growth 5Y22.67%
Sales Q2Q%9.64%
3.2 Future
- The Earnings Per Share is expected to grow by 5.89% on average over the next years.
- Based on estimates for the next years, UTI will show a quite strong growth in Revenue. The Revenue will grow by 8.84% on average per year.
EPS Next Y-31.19%
EPS Next 2Y-10.25%
EPS Next 3Y5.89%
EPS Next 5YN/A
Revenue Next Year9.48%
Revenue Next 2Y8.9%
Revenue Next 3Y8.84%
Revenue Next 5YN/A
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. UTI Valuation Analysis
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 39.13 indicates a quite expensive valuation of UTI.
- UTI's Price/Earnings ratio is in line with the industry average.
- UTI is valuated expensively when we compare the Price/Earnings ratio to 25.23, which is the current average of the S&P500 Index.
- Based on the Price/Forward Earnings ratio of 41.34, the valuation of UTI can be described as expensive.
- UTI's Price/Forward Earnings ratio is in line with the industry average.
- UTI's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.51.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.13 | ||
| Fwd PE | 41.34 |
4.2 Price Multiples
- UTI's Enterprise Value to EBITDA ratio is in line with the industry average.
- Based on the Price/Free Cash Flow ratio, UTI is valued a bit cheaper than the industry average as 60.27% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 129.41 | ||
| EV/EBITDA | 18.55 |
4.3 Compensation for Growth
- The decent profitability rating of UTI may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.59
EPS Next 2Y-10.25%
EPS Next 3Y5.89%
5. UTI Dividend Analysis
5.1 Amount
- UTI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
UTI Fundamentals: All Metrics, Ratios and Statistics
37.96
-1.7 (-4.29%)
Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)02-04 2026-02-04/amc
Earnings (Next)05-05 2026-05-05
Inst Owners97.17%
Inst Owner Change7.31%
Ins Owners2.7%
Ins Owner Change3.59%
Market Cap2.09B
Revenue(TTM)855.03M
Net Income(TTM)53.69M
Analysts81.82
Price Target38.42 (1.21%)
Short Float %6.37%
Short Ratio4.42
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0.03
Dividend Growth(5Y)-34.43%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.57%
Min EPS beat(2)28.91%
Max EPS beat(2)66.22%
EPS beat(4)4
Avg EPS beat(4)59.42%
Min EPS beat(4)28.91%
Max EPS beat(4)73.27%
EPS beat(8)7
Avg EPS beat(8)48.68%
EPS beat(12)11
Avg EPS beat(12)85.96%
EPS beat(16)14
Avg EPS beat(16)183.11%
Revenue beat(2)2
Avg Revenue beat(2)0.64%
Min Revenue beat(2)0.47%
Max Revenue beat(2)0.82%
Revenue beat(4)4
Avg Revenue beat(4)1.74%
Min Revenue beat(4)0.47%
Max Revenue beat(4)4.51%
Revenue beat(8)8
Avg Revenue beat(8)2.01%
Revenue beat(12)12
Avg Revenue beat(12)2.35%
Revenue beat(16)15
Avg Revenue beat(16)2.9%
PT rev (1m)0.64%
PT rev (3m)0.64%
EPS NQ rev (1m)-109.53%
EPS NQ rev (3m)-103.82%
EPS NY rev (1m)0.72%
EPS NY rev (3m)-1.83%
Revenue NQ rev (1m)-0.05%
Revenue NQ rev (3m)-0.45%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)0.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.13 | ||
| Fwd PE | 41.34 | ||
| P/S | 2.44 | ||
| P/FCF | 129.41 | ||
| P/OCF | 26.97 | ||
| P/B | 6.22 | ||
| P/tB | 7.29 | ||
| EV/EBITDA | 18.55 |
EPS(TTM)0.97
EY2.56%
EPS(NY)0.92
Fwd EY2.42%
FCF(TTM)0.29
FCFY0.77%
OCF(TTM)1.41
OCFY3.71%
SpS15.54
BVpS6.11
TBVpS5.21
PEG (NY)N/A
PEG (5Y)0.59
Graham Number11.54
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.44% | ||
| ROE | 15.98% | ||
| ROCE | 11.63% | ||
| ROIC | 8.69% | ||
| ROICexc | 11.82% | ||
| ROICexgc | 13.27% | ||
| OM | 8.38% | ||
| PM (TTM) | 6.28% | ||
| GM | 49.62% | ||
| FCFM | 1.89% |
ROA(3y)4.45%
ROA(5y)3.5%
ROE(3y)11.95%
ROE(5y)9.34%
ROIC(3y)7.27%
ROIC(5y)5.89%
ROICexc(3y)10.21%
ROICexc(5y)8.25%
ROICexgc(3y)11.54%
ROICexgc(5y)9.21%
ROCE(3y)9.72%
ROCE(5y)7.88%
ROICexgc growth 3Y34.26%
ROICexgc growth 5YN/A
ROICexc growth 3Y33.76%
ROICexc growth 5YN/A
OM growth 3Y17.03%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5Y53.06%
GM growth 3Y-13.36%
GM growth 5Y-8.21%
F-Score7
Asset Turnover1.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | 6.28 | ||
| Debt/EBITDA | 0.93 | ||
| Cap/Depr | 181.06% | ||
| Cap/Sales | 7.17% | ||
| Interest Coverage | 13.88 | ||
| Cash Conversion | 73.39% | ||
| Profit Quality | 30.06% | ||
| Current Ratio | 1.14 | ||
| Quick Ratio | 1.14 | ||
| Altman-Z | 4.06 |
F-Score7
WACC8.8%
ROIC/WACC0.99
Cap/Depr(3y)145.01%
Cap/Depr(5y)268.95%
Cap/Sales(3y)5.89%
Cap/Sales(5y)11.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y3.11%
EPS 5Y65.96%
EPS Q2Q%-42.5%
EPS Next Y-31.19%
EPS Next 2Y-10.25%
EPS Next 3Y5.89%
EPS Next 5YN/A
Revenue 1Y (TTM)12.59%
Revenue growth 3Y25.89%
Revenue growth 5Y22.67%
Sales Q2Q%9.64%
Revenue Next Year9.48%
Revenue Next 2Y8.9%
Revenue Next 3Y8.84%
Revenue Next 5YN/A
EBIT growth 1Y-0.64%
EBIT growth 3Y47.33%
EBIT growth 5YN/A
EBIT Next Year46.18%
EBIT Next 3Y27.41%
EBIT Next 5YN/A
FCF growth 1Y371.76%
FCF growth 3YN/A
FCF growth 5Y99.08%
OCF growth 1Y35.47%
OCF growth 3Y28.35%
OCF growth 5Y54.57%
UNIVERSAL TECHNICAL INSTITUT / UTI Fundamental Analysis FAQ
What is the fundamental rating for UTI stock?
ChartMill assigns a fundamental rating of 5 / 10 to UTI.
What is the valuation status for UTI stock?
ChartMill assigns a valuation rating of 2 / 10 to UNIVERSAL TECHNICAL INSTITUT (UTI). This can be considered as Overvalued.
Can you provide the profitability details for UNIVERSAL TECHNICAL INSTITUT?
UNIVERSAL TECHNICAL INSTITUT (UTI) has a profitability rating of 7 / 10.
Can you provide the financial health for UTI stock?
The financial health rating of UNIVERSAL TECHNICAL INSTITUT (UTI) is 5 / 10.
What is the earnings growth outlook for UNIVERSAL TECHNICAL INSTITUT?
The Earnings per Share (EPS) of UNIVERSAL TECHNICAL INSTITUT (UTI) is expected to decline by -31.19% in the next year.